Study guide
14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
Philippine Physician Licensure Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: PLE Structure, Eligibility & Study Strategy
1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan
2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle
2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction
3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems
3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments
4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems
4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation
5 Chapter 5: Physiology IV: Neurophysiology & Special Senses
5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses
6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death
6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death
7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning
7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws
8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics
8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics
9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics
9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock
10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection
10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology
11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology
11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura
12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology
12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors
13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry
13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism
14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry
14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back
15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes
16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin
16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands
17 Chapter 17: Anatomy III: Head, Neck & Histology
17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology
18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections
18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis
19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections
19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning
20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections
20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases
21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections
21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis
22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding
22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage
23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems
23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception
24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception
24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria
25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues
25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents
26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections
27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders
27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning
28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders
28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child
29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider
29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036
30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine
30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine
31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer
31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health
32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections
33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics
33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy
34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics
34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis
35 Chapter 35: Surgery I: Basic Surgical Principles
35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety
36 Chapter 36: Surgery II: Abdomen, Breast & Hernia
36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma
37 Chapter 37: Surgery III: Surgical Specialties
37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)
38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine
38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome
39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine
39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry
40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)
14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
Key Takeaways Explain This Topic AI
HMG-CoA reductase is the rate-limiting step of cholesterol synthesis; statins inhibit it, which raises hepatic LDL receptors and clears LDL.
ApoB-100 binds the LDL receptor, ApoC-II activates lipoprotein lipase, ApoE mediates remnant uptake and ApoA-I activates LCAT for reverse cholesterol transport by HDL.
Oxidized LDL taken up by macrophage scavenger receptors forms foam cells and fatty streaks; matrix metalloproteinases thin the fibrous cap, causing rupture and thrombosis.
The healthy heart gets about 60% to 90% of its ATP from fatty acid oxidation; ischemia shifts it to anaerobic glycolysis, with lactate accumulation and loss of contractility within about a minute.
Cardiac troponins rise about 3 to 4 hours after myocardial injury and stay high for 7 to 10 days; natriuretic peptides (BNP, NT-proBNP) rise with ventricular stretch and help diagnose heart failure.
Last updated: October 2026
Why this area matters
The TOS lists "biochemical mechanisms and properties underlying cardiovascular function and diseases such as heart failure, coronary artery disease, systemic atherosclerosis, infections, compensatory mechanisms to prevent organ dysfunction; myocardial energetics". Dyslipidemia, hypertension and diabetes drive the Philippine burden of ischemic heart disease and stroke. Lipid biochemistry underlies statin, ezetimibe and fibrate therapy in Pharmacology and Medicine.
Cholesterol Biosynthesis, HMG-CoA Reductase, and Statin Pharmacology
Cholesterol is synthesized from cytosolic acetyl-CoA in all nucleated cells, predominantly hepatocytes and steroidogenic tissues. Two acetyl-CoA molecules form acetoacetyl-CoA, which condenses with a third to generate HMG-CoA in the cytoplasm. The rate-limiting and committed reaction is catalyzed by HMG-CoA Reductase on the endoplasmic reticulum membrane:
HMG-CoA + 2 NADPH + 2 H + → HMG-CoA Reductase Mevalonate + 2 NADP + + CoA-SH \text{HMG-CoA} + 2\text{ NADPH} + 2\text{ H}^+ \xrightarrow{\text{HMG-CoA Reductase}} \text{Mevalonate} + 2\text{ NADP}^+ + \text{CoA-SH} HMG-CoA + 2 NADPH + 2 H + HMG-CoA Reductase Mevalonate + 2 NADP + + CoA-SH
Transcriptional Control: Sterol Regulatory Element-Binding Protein-2 (SREBP-2) upregulates HMG-CoA reductase gene expression when intracellular cholesterol is low. High intracellular cholesterol retains SREBP in the ER via SCAP (SREBP Cleavage-Activating Protein).
Hormonal Control: Insulin activates HMG-CoA reductase via dephosphorylation; glucagon and AMPK phosphorylate and inactivate it.
Pharmacological Inhibition: Statins (atorvastatin, rosuvastatin, simvastatin) are structural analogs of HMG-CoA that act as competitive, reversible inhibitors of HMG-CoA reductase. Decreased intracellular cholesterol upregulates LDL receptor (LDLR) expression on hepatocyte membranes, dramatically clearing atherogenic LDL particles from the circulation.
Lipoprotein Metabolism and Apolipoproteins
Lipoproteins are spherical macromolecular complexes composed of a hydrophobic core (triacylglycerols and cholesteryl esters) surrounded by an amphipathic shell of phospholipids, unesterified cholesterol, and apolipoproteins.
High-Yield Human Apolipoproteins
Apolipoprotein Primary Lipoprotein Association Physiological Function Clinical Significance
ApoA-I HDL Structural protein of HDL; activates LCAT Drives reverse cholesterol transport; low levels correlate with premature CAD
ApoB-48 Chylomicrons, Chylomicron remnants Mediates chylomicron assembly and secretion from enterocytes into mesenteric lymphatics Formed by post-transcriptional RNA editing (cytidine-to-uridine deamination creating a stop codon)
ApoB-100 VLDL, IDL, LDL Structural protein synthesized in hepatocytes; binds to the LDL Receptor (LDLR) High levels correlate with atherogenic particle count; defective in Familial Hypercholesterolemia
ApoC-II Chylomicrons, VLDL, HDL Obligate cofactor that activates endothelial Lipoprotein Lipase (LPL) Deficiency causes massive Type I hypertriglyceridemia and acute pancreatitis
ApoE Chylomicron remnants, VLDL, IDL, HDL Mediates receptor-mediated clearance of remnants via hepatic LDL receptors and LRP Homozygosity for ApoE2 causes Type III hyperlipidemia; ApoE4 allele confers high risk of Alzheimer disease
Lipoprotein Remodeling Enzymes
Lipoprotein Lipase (LPL): Anchored to capillary endothelial surfaces of adipose and muscle tissues; hydrolyzes core triacylglycerols in chylomicrons and VLDL into free fatty acids and glycerol.
Lecithin-Cholesterol Acyltransferase (LCAT / PCAT): Activated by ApoA-I on HDL; transfers a fatty acid from lecithin (phosphatidylcholine) to free cholesterol, forming hydrophobic cholesteryl esters that migrate to the HDL core, transforming nascent discoidal HDL into spherical mature HDL.
Cholesteryl Ester Transfer Protein (CETP): Facilitates the equimolar exchange of cholesteryl esters from HDL to VLDL, IDL, and LDL in return for triacylglycerols.
Familial Hyperlipidemias (Fredrickson Classification)
Type / Phenotype Defective Gene / Protein Elevated Lipoprotein(s) Primary Elevated Lipid Clinical Hallmarks & Risks
Type I (Familial Hyperchylomicronemia) Lipoprotein Lipase (LPL) or ApoC-II (Autosomal Recessive) Chylomicrons Triacylglycerols ( > 1000 mg/dL >1000\text{ mg/dL} > 1000 mg/dL ) Creamy supernatant layer over clear infranatant; eruptive xanthomas, hepatosplenomegaly, acute pancreatitis; no accelerated atherosclerosis
Type IIa (Familial Hypercholesterolemia) LDL Receptor (LDLR) or ApoB-100 (Autosomal Dominant) LDL Cholesterol (LDL-C > 200 − 500 mg/dL >200-500\text{ mg/dL} > 200 − 500 mg/dL in heterozygotes) Tendon xanthomas (Achilles and extensor tendons), xanthelasma, corneal arcus; severe premature CAD (infarction before age 20 in homozygotes)
Type IIb (Familial Combined Hyperlipidemia) Polygenic / Decreased LDLR and overproduction of ApoB LDL and VLDL Cholesterol and Triacylglycerols Common (1 in 200); accelerated CAD risk; associated with metabolic syndrome
Type III (Familial Dysbetalipoproteinemia) ApoE (Homozygosity for defective ApoE2 allele) IDL and Chylomicron remnants Cholesterol and Triacylglycerols Pathognomonic palmar xanthomas (orange creases), tuberoeruptive xanthomas; premature CAD and peripheral vascular disease
Type IV (Familial Hypertriglyceridemia) Hepatic overproduction or impaired catabolism of VLDL VLDL Triacylglycerols ( 200 − 500 mg/dL 200-500\text{ mg/dL} 200 − 500 mg/dL ) Associated with obesity, insulin resistance, type 2 diabetes mellitus; risk of acute pancreatitis at high concentrations
Type V (Mixed Hyperlipidemia) Defective LPL or ApoC-II with elevated VLDL Chylomicrons and VLDL Triacylglycerols and Cholesterol Creamy top layer with turbid infranatant; eruptive xanthomas, acute pancreatitis
Molecular Biochemistry of Atherogenesis: From Endothelial Injury to Plaque Rupture
Atherosclerosis is a chronic inflammatory and fibroproliferative disease of elastic and large muscular arteries triggered by subendothelial retention of ApoB-containing lipoproteins.
Endothelial Dysfunction and Subendothelial Retention: Chronic hemodynamic shear stress, cigarette smoke oxidants, hyperhomocysteinemia, or diabetes disrupts endothelial integrity. Circulating LDL enters the subendothelial space of the arterial intima, binding to matrix proteoglycans.
Oxidative Modification: Entrapped LDL is modified by reactive oxygen species (ROS) and myeloperoxidase into minimally oxidized LDL and extensively oxidized LDL (oxLDL) .
Monocyte Recruitment and Scavenger Receptors: OxLDL stimulates endothelial cells to express adhesion molecules (VCAM-1, ICAM-1) and Monocyte Chemoattractant Protein-1 (MCP-1). Monocytes transmigrate into the intima and differentiate into macrophages. Unlike the physiologic LDL receptor, macrophage Scavenger Receptors (SR-A and CD36) are not down-regulated by intracellular cholesterol accumulation. Macrophages uncontrollably endocytose oxLDL.
Foam Cell Genesis and Fatty Streak Formation: Macrophages engorged with cytosolic cholesteryl ester droplets transform into foam cells . Clusters of foam cells beneath the intact endothelium form the macroscopic fatty streak , the earliest visible atherosclerotic lesion.
Fibrous Cap Formation: Activated foam cells and T H 1 T_H1 T H 1 lymphocytes secrete inflammatory cytokines ( T N F − α TNF-\alpha TNF − α , I L − 1 IL-1 I L − 1 , I F N − γ IFN-\gamma I FN − γ ) and growth factors ( P D G F PDGF P D GF , T G F − β TGF-\beta TGF − β ). Platelet-Derived Growth Factor (PDGF) stimulates vascular smooth muscle cells (VSMCs) to migrate from the media to the intima, proliferate, and synthesize dense extracellular collagen, forming a protective fibrous cap over a necrotic lipid core.
Plaque Rupture and Acute Thrombosis: Inflammatory macrophages in vulnerable shoulder regions secrete Matrix Metalloproteinases (MMPs) (collagenases) that degrade the fibrous cap matrix. Thinning and rupture of the fibrous cap exposes subendothelial tissue factor and necrotic core thrombogenic lipids to circulating platelets and factor VII, triggering acute occlusive thrombosis and culminating in acute myocardial infarction or ischemic stroke.
Other atherogenic factors
Lipoprotein(a): LDL-like particles carrying apo(a) , which is structurally similar to plasminogen. It promotes both atherosclerosis and thrombosis. Levels are genetically determined.
Hyperhomocysteinemia: caused by B12, folate or B6 deficiency, renal failure or CBS mutations. It injures endothelium and favors thrombosis.
Small dense LDL and high triglycerides with low HDL, as in insulin resistance .
Smoking: oxidants and endothelial dysfunction. Diabetes: glycation and advanced glycation end-products. Hypertension: shear and stretch injury. Inflammation: high-sensitivity CRP.
Myocardial energetics
The heart beats continuously and consumes a great deal of ATP but stores very little. It must regenerate ATP from:
fatty acid beta-oxidation , which provides about 60% to 90% of ATP in the resting adult heart;
glucose, lactate and ketones.
Creatine phosphate buffers ATP and shuttles high-energy phosphate from mitochondria to myofibrils through mitochondrial and cytosolic creatine kinase.
In ischemia , oxygen falls and oxidative phosphorylation stops within seconds. The heart shifts to anaerobic glycolysis from glycogen. Lactate and H+ accumulate, creatine phosphate falls, and contractility is lost within about 60 seconds . Irreversible injury begins after about 20 to 30 minutes. Ion pumps fail, Na+ and Ca2+ accumulate, and arrhythmias follow.
In heart failure , the failing heart shifts toward glucose use, its creatine phosphate falls, and its mitochondria work less efficiently, an "energy-starved" state.
Thiamine deficiency (wet beriberi) impairs pyruvate dehydrogenase and causes high-output failure that responds dramatically to thiamine.
Biochemical markers of myocardial injury
Marker Rises Peaks Returns to normal Notes
Cardiac troponin I or T 3 to 4 hours (high-sensitivity assays detect earlier) 24 to 48 hours 7 to 10 days (troponin T up to 14 days) Most sensitive and specific ; key to the universal definition of MI; also raised in myocarditis, pulmonary embolism, sepsis and chronic kidney disease
- CK-MB 4 to 6 hours About 24 hours 48 to 72 hours Useful for detecting reinfarction because it falls early
- Myoglobin 1 to 2 hours 6 to 12 hours About 24 hours Very early but not cardiac-specific
- LDH-1 24 to 48 hours 3 to 6 days 10 to 14 days Historical "flipped" LDH pattern
- Heart failure: compensation becomes harm
When cardiac output falls, the body activates mechanisms meant to protect perfusion:
Sympathetic activation: catecholamines raise heart rate and contractility and constrict vessels. Chronically, they cause beta-receptor downregulation, myocyte toxicity and arrhythmias. Beta-blockers counter this.
Renin-angiotensin-aldosterone system: angiotensin II constricts vessels and promotes remodeling and fibrosis. Aldosterone retains sodium and water and causes myocardial fibrosis. This explains the benefit of ACE inhibitors, ARBs and ARNI, and mineralocorticoid antagonists.
Vasopressin: water retention leading to hyponatremia.
Natriuretic peptides (ANP, BNP): released when atria and ventricles are stretched. They cause natriuresis and vasodilation, but their effect is overwhelmed. BNP and NT-proBNP are diagnostic and prognostic markers. Sacubitril blocks neprilysin, the enzyme that degrades BNP.
The Frank-Starling mechanism and hypertrophy: initially compensatory, they later cause increased wall stress, fibrosis and remodeling.
SGLT2 inhibitors cause glycosuria, natriuresis and a metabolic shift, and reduce heart-failure hospitalization.
Infections and the heart (biochemical view)
Rheumatic fever: molecular mimicry between streptococcal M protein and cardiac myosin. ASO and anti-DNase B titers document a preceding streptococcal infection.
Infective endocarditis: bacteria adhere to fibrin-platelet vegetations through surface adhesins (dextran in viridans streptococci). Acute-phase reactants (CRP, ESR) are high. The anemia of chronic disease is mediated by hepcidin.
Sepsis: cytokines such as TNF and IL-1 and nitric oxide depress myocardial contractility. Lactate rises from poor perfusion and impaired mitochondrial use.
Diphtheria toxin inhibits protein synthesis by ADP-ribosylating EF-2, causing myocarditis. Chagas disease and viral myocarditis cause cardiomyopathy.